Tag

Lilly

All articles tagged with #lilly

business17 days ago•3 min saved

Sangamo Goes Chapter 11 as Lilly and Astellas Target Its Assets

Sangamo Therapeutics filed for voluntary Chapter 11 bankruptcy and cut about 40% of its staff as Lilly and Astellas act as stalking horse bidders to acquire key asset platforms, including AAV capsid delivery and gene-editing tools. Lilly is also eyeing the prion therapy ST-506, while Astellas pursues Fabry disease gene therapy ST-920; Giroctocogene fitelparvovec may be sold separately. The restructuring aims to maximize value amid cash constraints and creditor claims.

via BioSpace|

#asset-sale #astellas #bankruptcy

biotech18 days ago•2 min saved

Lilly grants single-patient compassionate-use access to retatrutide

Lilly has granted compassionate-use access to its obesity drug candidate retatrutide for a single patient, according to STAT’s exclusive reporting; The Readout also covers Pfizer’s lung-cancer trial results and other biotech news.

via statnews.com|

#biotech #compassionate-use #lilly

business25 days ago•2 min saved

Lilly Acquires 4E Therapeutics to Fast-Track Non-Opioid Pain Therapy

Eli Lilly has acquired Austin-based 4E Therapeutics to advance a non-opioid pain program that targets the MNK-eIF4E signaling pathway in peripheral sensory neurons. 4E’s lead MNK inhibitor 4ET1103 showed favorable Phase 1 safety, and Lilly will integrate 4E’s neuroscience capabilities into its broader pain portfolio. Terms were not disclosed.

via PR Newswire|

#4e-therapeutics #business #chronic-pain

business28 days ago•8 min saved

Lilly bets big on Ajax asset as early data show rapid JAK2 inhibitor activity in MF

Lilly’s up-to-$2.3 billion acquisition of Ajax Therapeutics is being justified by early AJX-101 data showing AJ1-11095, a Type II JAK2 inhibitor, produced rapid spleen size reduction and symptom improvement in pretreated myelofibrosis patients, with reductions in mutant JAK2 allele burden and a generally favorable safety profile though anemia and thrombocytopenia occurred; most patients remained on therapy, and the company plans a Phase 3 in second-line MF while expanding to other MF subtypes, signaling a potential challenge to Incyte’s Jakafi dominance and underscoring Lilly’s strategy to back de-risked, validated assets.

via Fierce Biotech|

#aj1-11095 #ajax-therapeutics #business

health1 month ago•2 min saved

Lilly’s next-gen obesity drug shows weight loss potential but safety signals need more data

Lilly’s obesity drug retatrutide, which previously showed rapid weight loss and diabetes benefits, yielded new safety data at the ADA meeting and in Lancet: in TRANSCEND-T2D-1, 7 of 403 participants on retatrutide had arrhythmias and 3 had major cardiovascular events versus none on placebo, a small event count that experts say is insufficient to draw firm cardiovascular risk conclusions.

via statnews.com|

#arrhythmias #health #lilly

business1 month ago•0 min saved

Lilly and Ascidian strike up to $1.9B RNA-editing pact for kidney disease

Eli Lilly and Ascidian Therapeutics unveiled a collaboration/licensing agreement potentially worth up to $1.9 billion to develop RNA-editing therapies for kidney diseases, following early data suggesting the approach may be safe in humans.

via Endpoints News|

#ascidian-therapeutics #biotech-deal #business

business1 month ago•2 min saved

Lilly inks up to $3B multi-program deal with Haisco to expand global portfolio

Eli Lilly expanded its global portfolio by signing a multi-program collaboration with China’s Haisco Pharmaceutical to co-develop up to five innovative targets across multiple therapeutic areas. Lilly will lead IND-enabling and may own global rights or rights outside Greater China per program, in exchange for $87 million upfront and up to $2.97 billion in milestones plus tiered single-digit royalties. The deal adds to Lilly’s ongoing spending spree to broaden its pipeline, which recently included a $1.2 billion Hanmi deal and other biotech acquisitions and partnerships.

via Fierce Biotech|

#business #haisco #ind-enabling

business1 month ago•2 min saved

Lilly inks $1.26B deal to license Hanmi's GLP-2 drug for short bowel syndrome

Eli Lilly is licensing Hanmi’s phase 2 GLP-2 agonist sonefpeglutide for short bowel syndrome, paying $75 million upfront and potentially up to $1.185 billion in milestones; Hanmi will complete its ongoing mid-stage SBS trial, while Lilly will initiate new studies based on existing data, positioning a monthly GLP-2 option to compete with Takeda’s Gattex as Lilly expands its GI/GLP-2 portfolio.

via Fierce Biotech|

#business #glp-2 #hanmi

health1 month ago•55 min saved

CVS Reinstates Zepbound Coverage and Adds Lilly’s Foundayo Obesity Pill

CVS Caremark will restore Eli Lilly’s obesity drug Zepbound to its commercial formularies on October 1 and add Lilly’s obesity pill Foundayo as a co‑preferred option, aiming to provide equal access and copays with Novo Nordisk’s Wegovy (as low as $25 a month for eligible commercially insured patients). All three of the nation’s largest pharmacy benefit managers now cover Lilly’s obesity portfolio, a move that could boost Foundayo sales in the second half of the year as employers and health plans seek more affordable GLP‑1 weight‑loss options.

via Reuters|

#cvs-health #foundayo #health

healthcare1 month ago•1 min saved

CVS Caremark Reverses, Restores Zepbound Coverage Amid Patient Backlash

CVS Caremark will reinstate Lilly’s weight‑loss drug Zepbound on its standard formulary by Oct. 1 after patient backlash over its prior removal, which had pressured some users to switch to Wegovy. The change, affecting about 25–30 million people, does not guarantee coverage for all employer plans but may widen access; Lilly says some private plans could offer as little as a $25 copay. Lilly’s Foundayo will also be added to the formulary starting Monday. Zepbound’s list price is around $1,086 per month before discounts, and a related class‑action lawsuit over the initial formulary decision remains active. Express Scripts and Optum Rx already cover Zepbound.

via NBC News|

#cvs-caremark #formulary #healthcare

business1 month ago•2 min saved

CVS Restores Zepbound Coverage, Adds Lilly’s Foundayo to Standard Plans

CVS Caremark will restore coverage for Eli Lilly’s Zepbound on Oct. 1 and start covering Lilly’s obesity pill Foundayo on June 1 on its standard drug plans, putting Lilly and Novo Nordisk on equal footing in major plans and expanding access for patients. The change follows CVS’s previous deal that favored Novo Nordisk’s Wegovy, and Caremark’s formulary will offer co‑preferred GLP-1 options for weight loss, though sponsors can opt out, meaning coverage isn’t guaranteed for all. CVS expects the shifts to drive 10%–15% savings in the weight‑management category as Lilly and Novo Nordisk negotiate pricing.”,

via CNBC|

#business #cvs-caremark #foundayo

business1 month ago•2 min saved

Lilly expands infectious-disease portfolio with three-broker vaccine acquisitions

Eli Lilly is buying Curevo, LimmaTech Biologics, and Vaccine Company for up to $3.8 billion in upfront and milestone payments to broaden its infectious-disease pipeline. Curevo brings a shingles vaccine candidate, LimmaTech adds a Staphylococcus aureus vaccine program, and Vaccine Company offers vaccines targeting flaviviruses and an EBV-focused program, signaling Lilly’s shift toward preventative vaccines and a strategy to build a diversified vaccine portfolio alongside its strong oncology and metabolic franchises.

via Fierce Biotech|

#acquisitions #business #curevo

business1 month ago•6 min saved

Lilly bets on prevention with three biotech acquisitions

Lilly announced agreements to acquire Curevo, LimmaTech Biologics and Vaccine Company to broaden its infectious-disease portfolio with vaccine-based prevention for shingles, bacterial pathogens and EBV-related disease, respectively. The deals could total up to $3.83 billion in potential cash payments, contingent on milestones and regulatory clearances, and closing is subject to customary conditions, reflecting Lilly's strategy to prevent disease at the source and address antimicrobial resistance.

via PR Newswire|

#antimicrobial-resistance #business #infectious-disease

business1 month ago•6 min saved

Lilly bets on prevention with triple acquisitions to boost infectious-disease portfolio

Lilly will acquire Curevo, LimmaTech Biologics, and Vaccine Company to broaden its infectious-disease portfolio, spanning a shingles vaccine candidate, a bacterial-pathogen vaccine platform, and an EBV-focused virus-like particle vaccine, for up to about $3.83 billion in cash and milestone payments, subject to closing conditions.

via investor.lilly.com|

#acquisitions #biopharma #business

business1 month ago•3 min saved

Lilly’s triple-hormone obesity drug posts strong Phase 3 weight loss, but data gaps temper optimism

Lilly’s triple-G obesity drug retatrutide met primary endpoints in Phase 3 TRIUMPH-1, delivering up to 28.3% weight loss at 80 weeks for the highest dose on the efficacy estimand (vs 2.2% for placebo). On the treatment-regimen estimand, weight losses were 17.6% (4 mg), 23.7% (9 mg) and 25% (12 mg) with placebo at 3.9%. A Week 104 readout for the top dose reached 29.9% among patients who stayed on therapy. The topline did not include sleep apnea or osteoarthritis pain data. Safety showed higher discontinuations at the high dose (11.3% vs 4.9% placebo) and notable dysesthesia (20.9% at high dose); GI adverse events were more common at the low dose. Analysts said the results meet key endpoints but didn’t exceed expectations, and Lilly is eyeing possible FDA submission this year amid competition from Wegovy and other obesity drugs.

via Fierce Biotech|

#business #lilly #obesity